Onderzoeker
Dahham Alsoud
- Disciplines:Gastro-enterologie
Affiliaties
- Translationeel Onderzoek van Gastro-enterologische Aandoeningen (TARGID) (Afdeling)
Lid
Vanaf15 sep 2019 → Heden
Projecten
1 - 1 of 1
- "Het voorspellen van therapie respons bij inflammatoire darmziekten "Vanaf23 sep 2019 → 23 sep 2023Financiering: Eigen Middelen zoals patrimonium, inschrijvingsgelden, giften, ....
Publicaties
1 - 10 van 18
- Beyond Discrimination: A Call for Comprehensive Assessment of Clinical Prediction Models in Inflammatory Bowel Disease(2024)
Auteurs: Dahham Alsoud, Ben Van Calster
- Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study(2024)
Auteurs: Dahham Alsoud, João Guedelha Sabino, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
- The Serum-Based Endoscopic Healing Index Can Monitor Therapeutic Response in Crohn's Disease(2023)
Auteurs: Dahham Alsoud, Bram Verstockt
Pagina's: 1703 - 1704 - Utility of the Serum-Based Endoscopic Healing Index in Monitoring Therapeutic Response in Ulcerative Colitis.(2023)
Auteurs: Dahham Alsoud, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire, Bram Verstockt
Pagina's: 1 - 9 - Comparative Effectiveness Research to Position Therapies in Ulcerative Colitis: How Fair Are the Comparisons?(2023)
Auteurs: Dahham Alsoud, Bram Verstockt, Séverine Vermeire
Pagina's: 1372 - 1373 - Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's disease(2023)
Auteurs: Nathalie Van den Berghe, Dahham Alsoud, Bram Verstockt, Séverine Vermeire, Paul Declerck, Debby Thomas
- Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis(2022)
Auteurs: Dahham Alsoud, Gert De Hertogh, João Guedelha Sabino, Marc Ferrante, Debby Thomas, Séverine Vermeire, Bram Verstockt
Pagina's: 1562 - 1570 - Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center(2022)
Auteurs: Dahham Alsoud, Bram Verstockt, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire
Pagina's: 1015 - 1020 - Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All(2022)
Auteurs: Padhmanand Sudhakar, Dahham Alsoud, Judith Wellens, Sare Verstockt, Kaline Arnauts, Bram Verstockt, Séverine Vermeire
Pagina's: 1306 - 1320 - Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD(2022)
Auteurs: Bram Verstockt, Dahham Alsoud, João Guedelha Sabino, Marc Ferrante, Séverine Vermeire
Pagina's: 1135 - 1142